Upstream Bio, Inc. (NASDAQ:UPB – Get Free Report) has earned an average recommendation of “Hold” from the five ratings firms that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $38.75.
A number of equities research analysts have recently weighed in on UPB shares. Mizuho lowered their target price on Upstream Bio from $51.00 to $50.00 and set an “outperform” rating for the company in a research note on Thursday, May 14th. Evercore lowered Upstream Bio from an “outperform” rating to an “in-line” rating and set a $15.00 target price for the company. in a research note on Friday, March 27th. Wall Street Zen lowered Upstream Bio from a “hold” rating to a “sell” rating in a research note on Saturday, March 28th. Finally, Weiss Ratings lowered Upstream Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, May 6th.
View Our Latest Research Report on UPB
Upstream Bio Trading Down 1.1%
Upstream Bio (NASDAQ:UPB – Get Free Report) last released its earnings results on Wednesday, May 13th. The company reported ($0.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.02). Upstream Bio had a negative net margin of 4,718.96% and a negative return on equity of 43.82%. The company had revenue of $1.03 million during the quarter, compared to the consensus estimate of $1.03 million. On average, equities research analysts predict that Upstream Bio will post -2.99 EPS for the current year.
Institutional Investors Weigh In On Upstream Bio
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. ADAR1 Capital Management LLC bought a new stake in shares of Upstream Bio in the 1st quarter valued at about $315,000. California State Teachers Retirement System raised its position in Upstream Bio by 170.7% during the 1st quarter. California State Teachers Retirement System now owns 39,661 shares of the company’s stock valued at $357,000 after purchasing an additional 25,009 shares during the last quarter. The Manufacturers Life Insurance Company raised its position in Upstream Bio by 51.2% during the 1st quarter. The Manufacturers Life Insurance Company now owns 15,338 shares of the company’s stock valued at $138,000 after purchasing an additional 5,191 shares during the last quarter. Quantinno Capital Management LP raised its position in Upstream Bio by 220.4% during the 1st quarter. Quantinno Capital Management LP now owns 49,389 shares of the company’s stock valued at $445,000 after purchasing an additional 33,974 shares during the last quarter. Finally, Entropy Technologies LP bought a new position in Upstream Bio during the 1st quarter valued at approximately $210,000.
About Upstream Bio
Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.
The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.
Read More
- Five stocks we like better than Upstream Bio
- Workday Validates AI Flywheel: Stock Price Recovery Begins
- HubSpot at 2019 Levels Is an Opportunity—Not a Warning
- Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus?
- Kiniksa Pharmaceuticals Still Has Room to Run After 100% Rally
Receive News & Ratings for Upstream Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Upstream Bio and related companies with MarketBeat.com's FREE daily email newsletter.
